Core Insights - OSE Immunotherapeutics acknowledges the FDA's Orphan Drug Designation for pegrizeprument (VEL-101), aimed at preventing organ rejection in liver transplant patients [1][3] Group 1: Product Development - Pegrizeprument is a novel investigational immunomodulatory monoclonal antibody fragment, originally developed by OSE Immunotherapeutics and licensed to Veloxis Pharmaceuticals in 2021 for all transplant-related indications [2][6] - The drug is designed to block CD28-mediated T cell activation while allowing CTLA-4 mediated immunosuppressive functions, indicating a dual mechanism of action [5] Group 2: Market Implications - The Orphan Drug Designation highlights the need for improved treatment options in solid organ transplantation, marking a significant milestone in the development of pegrizeprument [3][4] - Veloxis Pharmaceuticals is responsible for the global development, manufacturing, and commercialization of pegrizeprument, which is currently being developed for kidney transplantation [2][6] Group 3: Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with leading institutions to address unmet patient needs [7]

Core Viewpoint - OSE Immunotherapeutics has announced a strategic plan, with a focus on leadership changes and future directions for the company [1] Group 1: Leadership Changes - Marc Le Bozec has been appointed as the CEO of OSE Immunotherapeutics, having been elected to the Board of Directors on September 30 and appointed CEO shortly thereafter [1] - The company is in a transitional phase with new leadership aiming to implement the strategic plan [1] Group 2: Strategic Plan Discussion - The webcast will cover the strategic plan announced by the company, indicating a structured approach to future initiatives [1] - The discussion will include insights from key executives, including the CEO and CFO, highlighting their roles in the execution of the strategic plan [1]

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations NANTES, France – September 24, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) corrects the information relating to the total number of shares and voting rights comprising its share capital. As part of the preparation for the General Meeting on September 30, 2025, OSE identified a processing error related to t ...

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune checkpoint. Potential of signature to enhance personalized treatment for patients, regardless of cancer type. NANTES, France – April 30, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncolo ...